We take no money from the companies we review: no ads, no affiliate links, no sponsorships. Our editorial independence

HomeTrials › NCT07639021

Obesity & weight · Phase 2 · Recruiting now

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

NCT07639021 · Sponsor: Novo Nordisk A/S

What this trial means for you

This study is recruiting now at 24 US sites. It's studying NNC0662-0419, Semaglutide, NNC0662-0419 Placebo, Semaglutide placebo for obesity.

Who can joinAll sexes, 18 Years and older
Healthy volunteersNo, diagnosis required
What you'd takeNNC0662-0419, Semaglutide, NNC0662-0419 Placebo, Semaglutide placebo
Study length~13 months overall
Planned participants230
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening. * Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening. * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus.

Study sites by state

Alabama

  • Chambliss Clinical Trials, LLC, Montgomery · Recruiting now

California

  • FDRC, Costa Mesa · Recruiting now
  • Los Angeles Institute for Metabolic Research, Los Angeles · Recruiting now

Florida

  • Encore Medical Research LLC, Hollywood · Recruiting now
  • South Broward Research LLC, Miramar · Recruiting now
  • West Orange Endocrinology, Ocoee · Recruiting now

Illinois

  • Cedar-Crosse Research Center, Chicago · Recruiting now
  • Great Lakes Clinical Trials, Chicago · Recruiting now

Indiana

  • Midwest Inst For Clin Res, Indianapolis · Opening soon

Kentucky

  • L-MARC Research Center, Louisville · Recruiting now

Maryland

  • Endo And Metab Cons, Rockville · Recruiting now

Missouri

  • StudyMetrix Research LLC, City of Saint Peters · Recruiting now

New York

  • Great Lakes Medical Research, Westfield · Recruiting now

North Carolina

  • KDCILM, LLC & Accellacare US, Inc., Wilmington · Recruiting now

Ohio

  • Family Practice Center of Wadsworth Inc., Wadsworth · Recruiting now

Pennsylvania

  • UPA Ctr Weight and Eating Dis, Philadelphia · Recruiting now

Rhode Island

  • Clinical Res Collaborative, Cumberland · Recruiting now

Tennessee

  • Holston Medical Group_Bristol, Bristol · Recruiting now
  • Holston Medical Group, Kingsport · Recruiting now
  • Clinical Research Associates, Nashville · Recruiting now

Texas

  • PlanIt Research, PLLC, Houston · Recruiting now
  • Pinnacle Clinical Research, San Antonio · Recruiting now

Virginia

  • National Clin Res Inc., Richmond · Recruiting now

Washington

  • Rainier Clin Res Ctr Inc, Renton · Recruiting now

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently, so always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Keep researching on StudyBackedHealth